Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
Axsome Therapeutics is presenting ten data posters spanning its psychiatry and neurology portfolio at Psych Congress 2026, being held September 15-19 in New Orleans, Louisiana. The lineup includes new data in major depressive disorder and Alzheimer's disease agitation plus eight encore posters covering dextromethorphan-bupropion (AUVELITY) in MDD, solriamfetol (SUNOSI) in excessive daytime sleepiness, and AXS-12 in narcolepsy with cataplexy, including outcomes from the Phase 3 ENCORE trial.
Key figures
- Congress
- Psych Congress 2026
- Poster count
- 10
- Us condition prevalence
- over 150 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.